Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

JANX008

Bispecific antibody · Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3 · developed by Janux Therapeutics

Phase 1 Most advanced trial
JANX Developer
1 Registered trials

What is JANX008?

JANX008 is a protease-activated, tumor-activated T-cell engager that binds EGFR on tumor cells and CD3 on T-cells once its masks are cleaved in the tumor microenvironment. Its albumin-binding domain extends circulating half-life. It is being studied in non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, colorectal carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
epidermal growth factor receptor (EGFR), CD3
Mechanism
Immune activation, directed at epidermal growth factor receptor (EGFR) and CD3
Pathways
T-cell mediated cytotoxicity
Therapy area
Oncology
Developer
Janux Therapeutics (JANX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05783622 Phase 1 Non-Small Cell Lung Cancer Active not recruiting JANX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CarcinomaNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckTriple-negative Breast Cancer

Other drugs acting on EGFR

More from Janux Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.

Follow JANX, the company behind JANX008

See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JANX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.